Probiotic benefits for at-risk infantsMaternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant.
We conducted a study to see if giving probiotics to mothers during pregnancy and breastfeeding could help reduce eczema in infants at risk. This double-blind, placebo-controlled trial involved 241 mother-infant pairs, where mothers were given either specific probiotics or a placebo.
Our findings showed that infants whose mothers took Lactobacillus rhamnosus and Bifidobacterium longum had a significantly lower risk of developing eczema in their first two years. This suggests that probiotics can be a safe and effective preventive measure for high-risk infants.
Read More
Lactobacillus acidophilus helps eczemaLactobacillus acidophilus KBL409 Ameliorates Atopic Dermatitis in a Mouse Model.
We explored the potential of Lactobacillus acidophilus KBL409 in addressing atopic dermatitis, a common form of eczema. By using a mouse model induced by house dust mites, we found that administering this probiotic led to significantly lower dermatitis scores and less immune cell infiltration in the skin.
Additionally, L. acidophilus KBL409 reduced serum immunoglobulin E and influenced various cytokines linked to inflammation. It also positively affected gut microbiota and concentrations of beneficial compounds, hinting at a broader impact on our immune responses. Overall, our findings suggest that L. acidophilus KBL409 may be a promising probiotic for eczema management.
Read More
Lactobacillus L-92 shows eczema benefitsEfficacy of prolonged ingestion of Lactobacillus acidophilus L-92 in adult patients with atopic dermatitis.
We conducted a thorough investigation on the effects of Lactobacillus acidophilus L-92 in adults with atopic dermatitis.
In a placebo-controlled, double-blinded study, we observed 50 patients who consumed either L-92 or a placebo for 24 weeks.
Results showed that those taking L-92 had notable improvements in skin symptoms over time, including reduced severity and incidents of scratching.
Overall, the findings suggest that L-92 might play a beneficial role in managing eczema symptoms.
Read More
Probiotic reduces eczema prevalenceEarly supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization?
We explored the potential of Lactobacillus rhamnosus HN001 in reducing eczema among infants at high risk. Through a robust double-blind trial, expecting mothers took the probiotic from 35 weeks pregnant and continued while breastfeeding, while infants received it from birth to two years. Remarkably, this approach halved the prevalence of eczema by ages 2 and 4. Even better, the benefits seemed to last until age 6, showing promising potential in preventing eczema and associated allergic sensitization. However, another probiotic, HN019, did not show similar effects, suggesting specific benefits tied to HN001.
Read More
Lactobacillus rhamnosus reduces eczema prevalenceA protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years.
We conducted a robust study using a double-blind randomized placebo-controlled trial to explore the impact of Lactobacillus rhamnosus HN001 on eczema in young children.
Mothers supplemented with HN001 from the 35th week of pregnancy until 6 months of breastfeeding, while infants continued taking the probiotic until age 2.
Remarkably, we found that this approach halved the prevalence of eczema by age 2, and its protective effects persisted up to age 4. HN001 may be a promising preventive measure for infants at high risk of allergic diseases.
Read More